1304
HLAVNÍ506722701005185134178232252
TÉMA533422701003981147194
Inkretiny45473370100165488113148175191229265
a4828337010034
metabolický487833701005994121157195235250266296330369
syndrom526333701002865103142166204264
|5584227010018
101564222701002873102
/36458043010732
Vnitř3722804301074592111139166
Lék.3907804301074184122140
2024;70(2):97-1014067804301074487128168182224265290333355369414455478517556596
/47088043010732
VNITŘNÍ48058043010746107127172221281301
LÉKAŘSTVÍ5128804301074084130188235279325377399
www.casopisvnitrnilekarstvi.cz42580430107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
PROHLÁŠENÍ4856000974387144199239292335376430452
AUTORŮ:95860009749101144200246300316
Prohlášení12955980984573119166187229263305352373
o168859809845
původnosti:17525980984794135180228274320354384404424
Publikace21966010954082127144161195233269308
byla2524601095448098134
zpracována26796010953277101139175217253290333370
s307060109530
využitím31206010953675119152169194211277
uvedené34186010954279118163202246285
literatury372460109517345997121158183226249288
a403360109536
nebyla40906010954382127162180216
publikována43276010954488132150166200243279316359396
ani4744601095367996
zaslána48606010953371101118154197234
k511460109534
recenznímu516960109523629913718021325727448572109566108
řízení613721095234073112155172
do8047210954487
jiného910721095183477117160204
média.113372109566105150167203218
Střet1370718098426998141170
zájmů:15587180983679100169215234
Žádný.18127210954380125168202213
Financování:20457180984161108149195232277318359406427446
Podpořeno25097210954082127171215239278321364
grantem28927210954468105148172211276
IGA_LF_2023_00231887210951767115159197234269310349386425466507548585
a379372109536
MZ384872109563106
ČR39747210954585
–407972109540
RVO41387210954182136
(FNOl,42937210952158108163181195
00098892).45077210953980121161200240279317337349
Poděkování:48757180984590137180221266307348395416435
N/A.53307210955180122139
Registrace4858380984688135156190219248290326368
v86983809841
databázích:9278380984687116158205247284306342389408
N/A.13528410955180122139
Projednání15088380984573119141183231278319365387
etickou1911838098417192128170214261
komisí:21888380984186155176210231250
N/A.24568410955180122139
LITERATURA426114001234978134189250318368438498567
1.42513000853648
Saini4921301083326581118133
R,64413010833549
Badole71213010833568107145161196
SL.9261301083336478
Bioactive10221301083355189122154178193226260
Compounds130013010834077136175214252290329355
Increase16731301083155385107141173199234
Incretins19261301083145284106140162177215242
with21861301083516689127
Beneficial233113010833671109144161178210225257273
Effects26221301083335271105138162190
on283013010833776
Diabetes.4251402083456193132168190224250264
In:7071402083155365
Watson79014020835889111139177215
RD,10231402083368293
Dokken113414020834584115146180218
BB.13711402083357184
Glucose14731402083446098130167193228
Intake17201402083145274107137171
and190914020833270109
Utilization2036140208344678297112141175196212250288
in234214020831553
Pre-Diabetes24131402083355690113160176208247282305338365
and279614020833270109
Diabetes.4251502083456193132168190224250264
Academic70415020834173106145180238253285
Press.10041502083355690117143157
2015,117615020833468100130142
pp.13331502083397891
349-353.143915020833470103126159192225237
2.42516000853652
Samms49416020833265123181207
RJ,7191602083356274
Coghlan81016020834077117155170202240
MP,10671602083559195
Sloop11791602083334886125164
KW.136116020833595105
How148316020834483134
May163416020835487118
GIP17691602083435995
Enhance188116020833270108141179211244
the21431602083215994
Therapeutic225516020833271106128161200235273296311343
Efficacy2615160208333506886118151183217
of284916020833756
GLP-1?42517020834476112133163186
Trends6261702083335084122161187
Endocrinol82917020833270109147180201217255293309
Metab.115317020835590112145184197
2020;31:410-421.136517020833468101135148183214222257287319342379412443452
3.42518000853651
Maloney49018020835487102140179214245
A,74918020834156
Rosenstock81918020833573100135173199222259292322
J,115518020832436
Fonseca120518020833370109135170203235
V.145418020833645
A1513180208341
Model-Based156818020835593133168183205242275302337377
Meta-Analysis195918020835489111144167208246278294326353367393
of236618020833857
24243718020833466
Antihyperglycemic25171802083417910111615418522526028131933536742519020833165123138170
Drugs60919020834567105144170
for7931902083185677
Type88419020833260100136
21033190208334
Diabetes:10811902083456193132168190224250263
Comparison135819020834077135174207228244270308347
of171819020833757
Treatment17881902083335084116138196231269291
Effects20921902083335271105138162190
at229519020833254
Therapeutic236319020833271106128161200235273296311343
Doses.271919020834684111146173186
Clin4252002083405570108
Pharmacol54820020833573105126185217249286302
Ther.86520020833372107128139
2019;105:1213-1223.101920020833468100130143173205239250280309341371393424453488523535
4.42521000853651
Davies48921010834577109124159185
MJ,6872101083548092
Bergenstal7922101083357091129164201228251283298
R,110321010833649
Bode116521010833574113148
B,132521010833648
et138621010833456
al.;1455210108332476072
NN8022-1922154021010834489124159192227247277307340375
Study19282101083325391130161
Group.210221010834465102140179191
Efficacy2306210108333506886118150182216
of253421010833857
Liraglutide26042101083314667100139154191213229267302
for4252201083185678
Weight51722010835790106144182204
Loss7352201083326996122
Among87122010834199138176215
Patients11012201083356788104138176198226
With13412201083577396134
Type148922010833361101136
21639220108335
Diabetes:16882201083456193132167190223250263
The196522010833372107
SCALE208622010833373116148181
Diabetes22812201083466193132168190224251
Randomized254622010833568106145183242257286320359
Clinical4252302083405570108123155188203
Trial.644230208332496597112125
JAMA.78523020832464119161176
2015;314:687-699.97623020833468100130141176207238250286321354373410444479490
5.42524000853650
Gorgojo-Martínez49024020834482104142180196234257313346367392407445480509
JJ,10132402083254860
Basagoiti-Carreño10872402083366995128167206221244259281324357378400434472510
B,161124020833548
Sanz-Velasco167324020833265103133154190223239271297330366
A,205324020834155
et212224020833457
al.21932402083314760
Effectiveness22672402083325170104137161177209243281316343370
and265124020833270109
tolerability277424020832158741094252502083215493108124139161195
of63325020833757
orlistat703250208337597590116139172193
and91025020833270109
liraglutide1032250208315305184123138176198214252287
in133325020831452
patients13992502083387193108143181203230
with16432502083506688126
obesity178325020833777112139154176210
in200625020831553
a2072250208332
real-world21172502083215587102125176214236252290
setting:24212502083266183108123161200212
The264625020833372107
XENSOR27672502083387111542526020833280116
Study.5572602083325391130162172
Int7452602083145274
J834260208324
Clin8742602083405570108
Pract9972602083355689121145
2019;115726020833569100131143
73:e13399.13162602083346879114144174206240275286
6.42527000853652
Pratley4902702083355689111126161192
R,69627020833549
Amod75927020834199137177
A,95027020834055
Hoff101827020834483102121
ST,11532702083336776
et124227020833457
al.13122702083324860
Oral138627020834769102117
semaglutide151727020832661119151190206243266281320355
versus18852702083326688115152178
subcutaneous207727020832663102135173195228266301340378404
liraglutide2495270208315305184123138176198214252287
and279627020833270109
placebo4252802083395587119153192231
in67128020831553
type7402802083215595131
2887280208334
diabetes9362802083395486125160183217243
(PIONEER11952802083195469117162196228264
4):14752802083345163
a1554280208332
randomised,16012802083215492131169228243269304343356
double-blind,197328020833876114153169204227267283298336375388
phase237728020833877109136171
3a256328020833567
trial.2646280208321435890106119
Lancet.2780280208332651034252902083316587101
2019;394:39-50.54129020833468100130143178211247259294328351385419432
7.42530010853645
Chao48730020834078110148
AM,65230020834196110
Tronieri7793002083324987125140175196212
JS,10073002083245669
Amaro109330020834199131152189
A,129930020834155
Wadden137130020835789128167202240
TA.16273002083337085
Semaglutide172830020833368126158197212250273288327362
for21063002083195678
the22003002083226095
treatment23123002083224377109131189224262283
of261230020833757
obesity.268530020833877113140154177211221
Trends4253102083335084122161187
Cardiovasc6283102083407294132147185217250276308
Med.95231020835489129142
2023;33:159-166.110931020833569101136148183216227257287319343373405440454
8.42532010853652
Rezaei49532020833570100133168183
S,69632020833346
Tabrizi7603202083326099121137166181
R,95932020833650
Nowrouzi-Sohrabi102732020834483134155193231260276298329368406427460499515
P,156032020833540
et161832020833456
al.16923202083324760
GLP-1177032020834476111133163
Receptor195132020833671103137176198235257
Agonist222632020834179117156171197220
Effects24643202083335271105138162190
on267232020833775
Lipid27653202083324786102140
and42533010833269108
Liver5453301083324779113134
Profiles6913301083355693110127142176203
in90633010831552
Patients9713301083356788103137175196224
with12073301083516688126
Nonalcoholic134533010834583121153168200236274312328342374
Fatty17323301083326182106140
Liver18843301083324779113134
Disease:20303301083456186121153179213226
Systematic22683301083336289112145202234256271302
Review258333010833570102117152202
and279833010833169108
Meta-Analysis.42534010835490112145167208247279294326353368394408
Can84834010834073111
J974340108324
Gastroenterol101334010834477103127148185221259280314335373389
Hepatol.141734010834479118151173210226239
2021;2021:8936865.167134010833468101133141176210243274283318352385419455490524536
9.42535000853649
Sun49535010833370108
F,62435010833238
Wu68235010835895
S,79735010833346
Wang86335010835889127166
J,105035010832436
et110635010833457
al.11833501083324760
Effect12643501083335271105138162
of144635010833857
glucagon-like15243501083385391123156195233272294311326356390
peptide-1193535010833874113135151190225248279
receptor22343501083215588122161183220242
agonists249635010833271109148163189212240
on275735010833776
lipid2853350108315304253601083395493
profiles5333601083386097115132147182209
among75636010833290128167206
type9763601083225595131
21122360108334
diabetes:11703601083385385125160183216243256
a1440360108332
systematic14873601083265885108142200232254269301
review18033601083215587103137189
and200636010833270109
network21293601083387395148186208238
meta-analysis.238236010835792115147170202240272288320347361387401
Clin27983601083405570108
Ther.42537020833372107128138
2015;37:225-241.57937020833468100130141176208218253288322345375407438447
10.4253800085367085
Berberich5293802083357192131167188204236274
AJ,8223802083416880
Hegele92238020834479118153169204
RA.11453802083357893
Lipid12573802083324786102141
effects14173802083345473107140164191
of162838020833756
glucagon-like17043802083385391123156195233271294310325355389
peptide211338020833874113135150189224
12357380208334
receptor24103802083215587121160183219241
analogs.267038020833270103118156196222235
Curr4253902083407698119
Opin56039020834786102140
Lipidol.7153902083324786102140179195207
2021;32:191-199.93839020833468101132141176208221250281313331362392428439
11.4254000085366678
Dahl52240020834578116131
K,67140020833550
Brooks7394002083355794133163192
A,94940020834155
Almazedi102340020834156114146176210249264
F,130640020833238
et136240020833456
al.14364002083324861
Oral151540020834769102117
semaglutide165040020832661119151191206243266281320355
improves202340020831572112133170202237264
postprandial230540020833877104127167188221259298313345361
glucose26844002083385391123160187222
and42541020833270109
lipid547410208315306985123
metabolism,68441020835792114147186225241256282340353
and105041020833270109
delays11724102083387389121152179
gastric13644102083387097120142157189
emptying,156641020833492131154187203241280293
in187241020831553
subjects193841020832663102118153185209237
with21884102083516789127
type23294102083215595130
22473410208334
diabetes.25204102083385385125160182216243257
Diabetes279041020834561934254202083397496130157
Obes59742020834787123150
Metab.76242020835489112144184196
2021;23:1594-1603.97442020833468101132140175210221251281314349372403434470503515
12.4254301085366884
Novodvorský52543020834583115153192225262284311341375
P,91643020833640
Haluzík9734302083447692129158174205
M.119543020835468
The128043020833272107
Effect14034302083335271105138162
of158143020833857
GLP-1165543020834375111132163
Receptor183543020833570103136175198235256
Agonists210843020834179117156171197220248
on237243020833776
Postprandial24644302083357299122161183216254293308340356
Lipaemia.28364302083324742544020833972107164180212225
Curr6654402083407798120
Atheroscler80044020834162100135156194220253268303324
Rep.113944020833671110122
2022;24:13-21.127744020833468101136148183215227257287309339371380
13.4254501085366883
Mulvihill52445020835492108140156194209224239
EE.7794502083336579
Regulation87445020833570109147162195216232270308
of119845020833757
intestinal12714502083145274107134157173211243258
lipid1545450208315306985124
and168545020833169108
lipoprotein18094502083153069108148169207229262277315
metabolism214045020835893115148187226242257283340
by249645020833970
the25824502083226095
proglucagon-derived2693450208339609813715219042546020833164103141180202243277299314347381421
peptides86146020833874113135150189224251
glucagon11274602083385391123156195233271
like1413460208315306094
peptide152246020833974114136151190225
11762460208334
and181146020833169108
glucagon19344602083385491123156195233272
like2221460208315306094
peptide233046020833874113135150189224
2.256946020833447
Curr26314602083407697119
Opin276546020834787102140
Lipidol.4254702083314786101140178194207
2018;29:95-103.64847020833468100131143178212225260294316347379412424
14.4254801085366984
Sun52948020833270108
F,65648020833339
Wu71448020835895
S,82848020833345
Guo89348020834482120
S,103348020833245
et109748020833457
al.11734802083324760
Impact125348020831572112145177201
of147448020833756
GLP-1155048020834375111132163
receptor17334802083205487121160182219241
agonists199348020833271109148163189212240
on225248020833876
blood23484802083385492131171
pressure,25384802083396095121148185206240252
heart2810480208337724254902083325378
rate5174902083205375109
and64049020833170109
hypertension76349020833768108143164189223261287302340379
among115649020833189127166205
patients13754902083397293109143181203231
with16204902083506688126
type17604902083225696131
21905490208334
diabetes:19534902083395486125160183216243256
A2223490208341
systematic22784902083265885109142200233254270302
review25944902083205487102137188
and279649020833270109
network4255002083387395148186207238
meta-analysis.67850020835793115148170202240273288320347362388401
Diabetes10955002083456193132167190223250
Res13615002083357097
Clin14735002083405570108
Pract.15965002083355689121145159
2015;110:26-37.177050020833468100130141171199230243278312335368400406
15.4255101085366780
Wang51951020835787124162
B,69451020833647
Zhong75551020833874111148185
J,95451020832435
Lin10035102083314582
H,109951020834455
et116851020833455
al.12375102083314557
Blood13085102083354986123161
pressure-lowering14835102083395992117142178198231252267304354387407421457495
effects19925102083345271104135158184
of219051020833755
GLP-1225951020834374109128158
receptor24305102083215485117155176211232
agonists267551020833270107144157182204230
exenatide4255201083346395131161181194231264
and69852010833167104
liraglutide:812520108314274777114128163184197234266277
a1099520108331
meta-analysis113952010835790110141161192227258271301326339363
of151152010833755
clinical1575520108331445793106136167180
trials.176552010832141548498122134
Diabetes19085201083455888125159179211236
Obes215352010834684117142
Metab.230552010835386107137174185
2013;15:737-749.25005201083336595123132161188198229261291308337365396405
16.4255300085366985
https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.15922526530108338598312315016218920926031436737841245048249853657459563366668170772175978081884588091893496099310241037106810951126115711781207122212431275128813191350138613991426146415031542155815951627163616671697172917621797
17.4255400085366776
Ribeiro-Silva5155401083355190125141162199222254268283316349
JC,8775401083246578
Tavares9685401083326092125146180207
CAM,118854010834082138151
Girardi13525401083445981114135173188
ACC.155354010834180118131
The169754010833372107
blood18175401083395593131171
pressure20015401083396094121148185206240
lowering225454010831553104138160175213252
effects25195401083345473107140164191
of272354010833857
glucagon-like2793540108338539142555010833164103141180202219234264298
peptide-173655010833974114136151190225248279
receptor10285501083215587121160182219241
agonists:128255010833271109148163189212240252
A1548550108341
mini-review160255010835873111126148170204236252287338
of195355010833757
the20235501083226095
potential213155010833978100134172193208240256
mechanisms.240055010835893125163196234249275332359372
Curr27865501083407697119
Opin42556020834787102140
Pharmacol.58156020833572104126184216249285301314
2023;91156020833468101136147
69:102355.10735602083346881111143176210243276288
18.4255700085366985
Sharma52457020833270103124182215
A,75257020834155
Verma8205702083366890148180
S.101457020833245
Mechanisms107357020835489122160192230245271329355
by144157020833970
Which152557020835796111143181
Glucagon-Like-Peptide-117195702083446097129162201239278300333349379413436473507546568583622657680711
Receptor244357020833570103137176198235257
Agonists2713570208341791171561714255802083264977
and51758020833270109
Sodium-Glucose64158020833270110125163220243289305343375412439474
Cotransporter-211305802083407798120153191217256295317341375396416447
Inhibitors15925802083155391106145160183220241269
Reduce187558020833671110148180214
Cardiovascular21045802083407294132147185217250276309346362394415
Risk25345802083355177107
in265658020831452
Adults272358020834179117132155182
With4255902083577496134
Type57459020833361101136
2726590208334
Diabetes7755902083456193132168190224251
Mellitus.104159020835489105120135157195222235
Can129259020834072110
J1418590208324
Diabetes.14575902083466193132168190224251264
2020;173759020833468101135148
44:93-102.19005902083347183118151173204235268281
19.4256000085366982
Marso52360020835487108135174
SP,7136002083326771
Daniels80160020834577115130165180206
GH,102360020834489102
Brown-Frandsen11416002083355794145183206240260293331370396431469
K,162660020833550
et169260020833456
al.17646002083324760
LEADER184060020833165107153187222
Steering20786002083335487123144160198237
Committee;233160020834077135193208230255288324336
LEADER268360020833165107153187222
Trial425610208333506597113
Investigators.5576102083155384118145168184222255277313335362376
Liraglutide9526102083324768101140155193215231270304
and127661020833169109
Cardiovascular14046102083407394132147185217250276309346362394415
Outcomes183861020834786108139176234269296
in215361020831553
Type222561020833360100136
22380610208334
Diabetes.24346102083456092132167189223250264
N2717610208345
Engl278161020833270109124
J425620208324
Med.46462020835590130143
2016;62262020833468100131144
375:311-322.7816202083346699110145176204222255287322334
20.4256301085367287
Marso52863020835487108135174
SP,7176302083336872
Bain8056302083356883121
SC,9426302083337386
Consoli104463020834077115141180196211
A,127063020834155
et134163020833456
al.14136302083324760
SUSTAIN-6148963020833376108142179194240262299
Investigators.18046302083155384119145169184223255277314335362376
Semaglutide219663020833267125158197212249272287326361
and257363020833270109
Cardiovascular269763020834073941321481864256402083326591123161176209230
Outcomes67064020834786108139176234269296
in98164020831553
Patients10496402083356789104139177198226
with12906402083516789127
Type143364020833260100135
21584640208334
Diabetes.16336402083456193132168190224251264
N1913640208344
Engl197364020833270109124
J2113640208324
Med215264020835490129
2016;229664020833569100132144
375:1834-1844.24556402083346699110140171205240263294325362398411
21.4256501085367082
Gerstein52265020834479100128151185200238
HC,7746502083458598
Colhoun8876502083407793131169207245
HM,114765020834499113
Dagenais127465020834678117152190222237263
GR,15526502083448094
et166165020833456
al.17326502083324760
REWIND180765020833569128144189235
Investigators.20576502083155384118145168183222255276313335362376
Dulaglutide24486502083458398131170185223245260299334
and279765020833270109
cardiovascular4256602083316485123139177208241268300338353385407
outcomes8496602083377598128165224259286
in115266020831452
type12226602083215595130
21370660208334
diabetes14216602083385385124160182216243
(REWIND):16816602083195488147163208254272284
a1982660208332
double-blind,203166020833876114153169204227267283298336375388
randomised24366602083215492131169227242268303343
placebo-controlled2796660208339558742567020833165104143166200237275297318356371387421461
trial.901670208322435991106119
Lancet.103667020833164102135168191204
2019;125567020833468100130143
394:121-130.141467020833467103115145175206225256285320333
22.4256801085367288
Hernandez52968020834479100139171209248283313
AF,8576802083417480
Green9536802083446599135173
JB,11416802083256173
Janmohamed12306802083245694152190229261319354394
S,163968020833346
et170068020833457
al.17726802083324760
Harmony18486802083447698156194233263
Outcomes212768020834786108139176234269296
committees243968020833168126184199221246279315342
and279668020833270109
investigators.4256902083155384118145168183222255276313335362376
Albiglutide8186902083415695111150165202225240279314
and114969020833270109
cardiovascular12756902083316485123139177209242268300338353386407
outcomes16996902083377598129165224259286
in200269020831452
patients20716902083397294109144182203231
with23196902083516689127
type24636902083225695131
22611690208334
diabetes26636902083385385124160182216242
and42570020833270109
cardiovascular5507002083326586124139177209242268301338354386407
disease9747002083385379114146172207
(Harmony11987002083196395116175213252282
Outcomes):149770020834785108139176234269296313325
a1838700208332
double-blind,188770020833876114153169204227267283298336375388
randomised22917002083215492131169228243269304343
placebo-26517002083395587119153192231254
-controlled4257102083215591130151173210226241276315
trial.756710208321435890106119
Lancet.89071020833165103135169191204
2018;111071020833468100131143
392:1519-1529.126871020833468101113143173204234258289319352386397
23.4257200085367489
Gerstein53572010834480102130154188203242
HC,79872010834586100
Sattar9197201083326688113147168
N,110872010834559
Rosenstock118872010833574102137176203227264298328
J,153772010832537
et159572010833457
al.16737201083324861
AMPLITUDE-O175572010834298135167182217263310344366417
Trial2193720108333506699115
Investigators.23297201083155385120147171187226259281319341369383
Cardiovascular2733720108340749513415042573010833870104131164203219252273
and71973010833371111
Renal85173010833672111144160
Outcomes103273010834787110141179238274301
with13547301083526891130
Efpeglenatide15057301083335293129170185221260293315331371406
in193273010831554
Type200773010833361102138
22166730108335
Diabetes.22227301083466295135171194228256270
N2513730108345
Engl257973010833372112128
J2728730108324
Med277373010835591132
2021;385:896-907.42574010833468101133141176210244255290324360383418454486493
24.30471300085377288
Lincoff31571301083324887120158178198
AM,337613010834299113
Brown-Frandsen35101301083365896149188211246267301340380407443482
K,401313010833651
Colhoun40851301083417996134174213252
HM,4358130108345102116
et449513010833457
al.45741301083324862
SELECT46571301083336698133174211
Trial48891301083335167100116
Investigators.50261301083155487122150173189229262285323345373387
Semaglutide543513010833369304714010835891131146185208223263298
and336614010833271111
Cardiovascular34981401083407495134150188221254281314353368401423
Outcomes394214010834786109141178238273301
in426414010831453
Obesity433814010834788124152167190224
without45831401083516790129168207230
Diabetes.48341401083456194134170193227255268
N5123140108346
Engl519014010833371111127
J5337140108325
Med.538314010835591131144
2023;389:2221-2232.304715010833468101136147182217251264299334369400419450485519552564
25.30471600085367489
Ussher31571601083447198136172194
JR,33721601083246176
Greenwell346916010834466101137176227263279294
AA,378416010834286100
Nguyen390516010834686124157192231
MA,415716010835598112
et429016010833557
al.43681601083334962
Cardiovascular44511601083407496135150189222255282315354370402424
Effects48961601083335372107140165193
of511016010833858
Incretin-Based51891601083155487108143166182221244281315304717010832662101
Therapies:316917010833372108129162202217252280292
Integrating34821701083155375109149170203225241279318
Mechanisms382117010835490123161194232247274332358
With42001701083587496135
Cardiovascular43561701083407394133148186218252278311349365397418
Outcome479517010834786109140177236271
Trials.5087170108332506598113139153
Diabetes.52611701083456193133169191225252266
2022;71:173-183.304718010833468101136148181214222252281316337368399433446
26.30471900085367187
Nauck314819020834577115147177
MA,333819020835597111
D‘Alessio34621902083455896112146173200215253
DA.372819020834585100
Tirzepatide,38411902083334970101135174207229244283318330
a4184190208332
dual422919020833976108124
GIP/GLP-143661902083445995116159191226248278
receptor46581902083205487121160182219241
co-agonist49121902083316891124163201239254280304
for52291902083185678
the53201902083216095
treatment54281902083224377304720010833254112147185207
of327420010833757
type33512001083225696131
23503200108334
diabetes35572001083385486125161183217244
with38212001083516689127
unmatched396820010833876134166188219257292331
effectiveness43202001083345372107140164179212246284319346373
regrading47132001083215595116149188203241280
glycaemic50142001083385385117149184242258290
control532420010833168107128150187203
and304721010833270109
body317121010833978117149
weight333621010835085100138176198
reduction.35492101083215595132164188204242280293
Cardiovasc38582101083407294132147185217250276309
Diabetol.41822101083456193132167190227243256
2022;21:169.445321010833468101136148183215223253284318329
27.30472200085367180
Frías31412202083325268100126
JP,32822202083246064
Davies336122020834577109124159186
MJ,35622202083548092
Rosenstock366822020833674101136174200223260293323
J,400522020832537
et405622020833456
al.41272202083324760
SURPASS-2420122020833376112148186220252275305
Investigators.45212202083155384118145168184222255276313335362376
Tirzepatide49112202083335071101136175208229245284319
versus52442202083326687114152178
Semaglutide543622020833368304723020835790129144182204219258293
Once335323020834786118152
Weekly351823020835790126156173204
in373523020831553
Patients38012302083356789104139177198226
with40402302083506689127
Type418023020833260100135
24328230208335
Diabetes.43762302083456192132167190223250264
N4653230208344
Engl471023020833371110125
J4848230208324
Med.488523020835590129143
2021;385:503-515.504123020833468101132140175210244255290324357379413444474486
28.30472400085367288
Jastreboff31552402083245683106127161201240259278
AM,345324020834196110
Aronne358224020834162100138176211
LJ,38122402083325971
Ahmad390224020834179137170209
NN,413024020834590103
et425224020833456
al.43282402083314760
SURMOUNT-1440724020833376112167215260305339357388
Investigators.48152402083145284118145168183222254276313335362375
Tirzepatide52102402083324970101135174207229244283318
Once304725020834786118151
Weekly321425020835790126156173204
for34342502083185677
the35272502083216095
Treatment36372502083325084116137195230269290
of394225020833857
Obesity.401425020834787123149164187220230
N4260250208344
Engl432025020833270109125
J4460250208324
Med.449925020835590129143
2022;387:205-216.465725020833468101136148183217250261296330364386417448479493
29.30472600085377488
Garvey315726010834579101137172205
WT,338426010835997106
Frias35122601083335370103131
JP,36642601083256267
Jastreboff37532601083255886110132167208248269288
AM,406326010834299114
et419826010833558
al.42782601083324962
SURMOUNT-2436226010833378115172222268315350369402
investigators.47852601083155487122150174191231264287325348376391
Tirzepatide51972601083335173105140181215238254294330
once304727010833776108142
weekly320327010835185121151168199
for34172701083185678
the35092701083226095
treatment36192701083214377109131189224262283
of391727010833757
obesity398827010833877113140154177211
in421327010831553
people428027010833975113153169204
with44982701083516689127
type46402701083215595131
24785270108335
diabetes48342701083385385125160183216243
(SURMOUNT-2):50922701083185093129185233277322356375406424436
a3047280108333
double-blind,310328010833979119160177213238279296312352393406
randomised,35322801083225696137177237253281317359372
multicentre,392728010836099115139155189224264286309345358
placebo-controlled,43082801083405790124159200241265301339379402425464481497533575588
phase491928010834080114142179
35121280108335
trial.5179280108322456295112126
Lancet532828010833267107140176199
2023;402:613-626.304729010833468101136147182218251263299329359381418452485498
30.30473000085367287
Aronne314930020834162100138176211
LJ,33743002083325971
Sattar34593002083336688112145166
N,363930020834558
Horn371130020834483104143
DB,38683002083468294
et397730020833456
al.40483002083314760
SURMOUNT-4412230020833376112167215260305339357394
Investigators.45303002083155384119145169184223255277314335363376
Continued492130020833976115136152190227262302
Treatment52373002083335084116138196231269290
With30473102083577496134
Tirzepatide31963102083335071101135175208229245284318
for35303102083185677
Maintenance362231020835587102140162196234266304336370
of400731020833756
Weight407931020835790105144182204
Reduction429831020833570110147179204219257295
in460831020831553
Adults467631020834179117132155182
With48733102083587496135
Obesity:502331020834786122149164186220233
The527131020833372107
SURMOUNT-45393310208333761123047320208354102147192226245281
Randomized334332020833669107146184242257286320360
Clinical37183202083405570108123155188203
Trial.3937320208332506597113125
JAMA.407832020832464119161176
2024;331:38-48.426932020833569102133145180213244253288322345382418431
31.30473300085367082
Wadden315033010835889129168203242
TA,34123301083337185
Chao351733010834179111150
AM,368833010834197110
Machineni381933010835588120158174212247286301
S,414033010833346
et420733010833456
al.42843301083324861
Tirzepatide43653301083335071102137176210232247286321
after47073301083325176110132
intensive48603301083145274108147173188221256
lifestyle5136330108315305085112135169185220
intervention53773301083155375109130304734010833266104126141179217
in328434010831452
adults335634010833170108123146173
with35493401083506688127
overweight369534010833769103125178212228266304326
or404034010833859
obesity:411934010833776112139154176210223
the43623401083216094
SURMOUNT-3447634010833276112167215259305339357390
phase488534010833977109136171
35075340108334
trial.5129340108321435991106119
Nat52673401083457799
Med.538534010835590129143
2023;29:2909-2918.304735020833468101136147182216229265299334370393424458490521535
32.30473600085367186
Wilson31513602083577489115153191
JM,33603602083247992
Nikooienejad34703602083456090127166181216254289304336376
A,386336020834155
Robins393636020833573113128166193
DA,41463602083458599
et426336020833456
al.43373602083314760
The441436020833372107
dual453836020833976108124
glucose-dependent46793602083385491123160187222245285320360395433472507545567
insulinotropic5263360208315537911613214718522324530473702083215897113145
peptide320937020833974114136151190225
and345137020833270109
glucagon-like35773702083385491123156195233272294311326356390
peptide-1398437020833974113136151190225248279
receptor42803702083205587121160182219241
agonist,453837020833271109147163189212225
tirzepatide,4780370208322375889123162195217232271306318
improves511537020831573112133171203237264
lipoprotein5396370208315306910830473802083396097119153168206
biomarkers32713802083385492150182204234268290317
associated36053802083325985123156171203225259298
with39213802083506688126
insulin40653802083155279116131146184
resistance4267380208320548196122145178216248282
and456638020833270109
cardiovascular46933802083316485123138176208241268300338353385406
risk5117380208321366292
in522738020831452
patients52973802083387193108143181203230
with30473902083516689127
type31893902083225595131
23335390208334
diabetes.33853902083385385124160182216243256
Diabetes36573902083456092132167189223250
Obes392239020834787123149
Metab.408739020835489112144184196
2020;22:2451-2459.429839020833569102136149184218231266298331362380411443476508519
33.30474000085367186
Wilson31504002083577489115153191
JM,33584002083247993
Lin34674002083324785
Y,356940020833543
Luo362940020833168106
MJ,37524002083548092
et386140020833456
al.39344002083324760
The401140020833271106
dual413440020833876108123
glucose-dependent42744002083385391123160187222245285320359395433472507545567
insulinotropic48574002083155379116132147185223245266303343359391
polypeptide5264400208339789412516520124030474101083223776111
and317841010833270109
glucagon-like33074101083385491123156195234272295311326356390
peptide-1371741010833975114136151190225248279
receptor40164101083215588122161183220242
agonist427841010833271109147162189212
tirzepatide4510410108322375889123162195217232271306
improves483641010831573112134171203237264
cardiovascular51204101083326486124139177209242268301338354386407
risk3047420108321366292
biomarkers31554201083395492150183204235269290317
in348842010831552
patients35564201083397294109144182203231
with38034201083506688126
type39454201083225695131
24092420108334
diabetes:41424201083385385124160182216243255
A4413420108341
post447042010833877104127
hoc461342010833775108
analysis.473742010833270102117149176191217231
Diabetes49834201083466193132168190224251
Obes525042010834786122149
Metab.54154201083548930474302083225494106
2022;24:148-153.316843020833569102136149184216228257289325347378408441454
34.30474400085367388
Kanbay314944020833568107146179209
M,337244020835568
Copur345444020834077117155176
S,364444020833245
Siriopol3703440208333476884122162200216
D,393344020834656
et400344020833457
al.40744402083314760
Effect41484402083325170105137161
of432344020833757
tirzepatide4394440208321375888122162195216232271305
on471344020833876
blood48034402083395593131171
pressure49884402083396094121148185206240
and524244020833270109
lipids:5365440208315306984123149162
A3047450108341
meta-analysis310045010835792114146168200238270285316343357383
of349645010833756
randomized35644501083215391129167225240268302341
controlled391845010833167105126147184200215249288
trials.4219450108321425889104130143
Diabetes43754501083456092131166188221248
Obes463545010834786121148
Metab.479545010835489111143182194
2023;25:3766-3778.500245010833468100134146180215225260292323358382414445479512525
35.30474600085367186
Sattar31514601083326587111144165
N,333546010834457
McGuire341146010835487132170185206240
DK,36694601083468196
Pavo37834601083366899137
I,393846010831528
et398446010833456
al.40594601083314760
Tirzepatide41374601083334971101135174207229245283318
cardiovascular44744601083316485123138176208241268300338353385406
event489946010833466100138160
risk5077460108321376393
assessment:51884601083325885120147173231266304326339
a3047470208332
pre-specified30944702083396094118144183219252267284301336376
meta-analysis.348547020835792115148170202240273288320347362388401
Nat39024702083447798
Med.401647020835489129142
2022;28:591-598.417347020833469101136149184217230265297329348382414449463
36.30474800085377694
Tschöp31664801083335893134175218
M,340848010835672
Nogueiras350548010834687130170208225249285314
R,384448010833652
Ahrén392148010834283107144185
B.413048010833752
Gut420748010834586111
hormone-based434348010833879104166207248286312355391420458500
pharmacology:486848010834081116140202237272312330372414449465
novel535748010833980115152170
formulations30474901083195882143182200234257275315355384
and345449010833373114
future35924901083185984124147183
possibilities379949010833980108137154195212229246270287324353
for41764901083185882
metabolic428249010835895119154195236254271305
disease46104901083395684121155184221
therapy.485449010832263100123158199233244
Diabetologia.51224901083466397139176201240257298339356390405
2023;66:1796-1808.304750010833470104140153190227241272303338375399432464501538552
37.30475100085377383
Tan315451010833463103
TM.328151010833391106
Co-agonist341151010834179104138179219259275303327
therapeutics37625101083226299122156197234274298314348377
come416351010833270131168
of435551010833859
age443851010833273110
for45725101083195881
obesity.467751010833880117145161185220231
Nat493251010834680103
Rev505951010833673107
Endocrinol.519051010833373114154188210227267307324338
2023;19:66-67.304752010833468101136147177208221256292315352385391
38.30475300085367288
Melson314953020835490105131169208
E,337153020833246
Ashraf343153020834168106127160179
U,362453020834455
Papamargaritis369353020833567106139197229250289321342358380395421
D,412853020834657
Davies419953020834577109124159186
MJ.43995302083548093
What450653020835796128150
is467053020831541
the47255302083216095
pipeline48345302083385493128144159197232
for50805302083185677
future51715302083195880118139173
medications53585302083589313214730475402083316486101139178204
for32665402083195678
obesity?335954020833777113139154177210234
Int36085402083155375
J3698540208324
Obes373754020834787123150
(Lond).39025402083185087126165184195
2024;411354020833468101133145
doi:42735402083387692104
10.1038/s41366-024-01473-y.43925402083346678109140174208233258294324354388424447485517549572610641672704739761792802
39.30475500085367185
Coskun315055020834077104134172210
T,337855020833342
Urva343855020834465100132
S,358955020833245
Roell365355020833573109124140
WC,381155020835797110
et394055020833456
al.40155502083314760
LY3437943,40935502083326397133165197231267299311
a4423550208332
novel447355020833876108142158
triple4649550208322435998114149
glucagon,48165502083385491123156195233272284
GIP,5119550208344599599
and523755020833270109
GLP-1536455020834476112133164
receptor30475602083215587121160182219241
agonist330256020833271109147163189212
for35285602083185677
glycemic36205602083385385116150208223255
control388956020833168106128149187203
and410656020833170109
weight422956020835085100139177198
loss:44415602083155380106119
From45745602083325289148
discovery47365602083385379111148180214236270
to502056020832158
clinical50925602083324762100115147180195
proof53015602083396098136156
of547156020833756
concept.304757020833168107139172212234247
Cell33095702083407490105
Metab.342957020835590112145184196
2022;34:1234-1247.364157020833468101136148183218231260290325360383414444476508514
40.30475800085367591
Rosenstock316058010833575102138177204228266300331
J,351358010832437
Frias35725801083325369102130
J,372458010832437
Jastreboff37835801083245785109131166206246267286
AM,409158010834197112
et422558010833457
al.43045801083324862
Retatrutide,43885801083357194128150173212235252291327340
a4750580108332
GIP,48045801083446097102
GLP-1492858010834477113135167
and511758010833271111
glucagon52505801083385493126160200239278
receptor30475901083215689124164187225248
agonist,331759010833272111150166193218232
for35715901083185779
people367259010833976115156173209
with39035901083506790129
type40545901083225798134
24210590108335
diabetes:42675901083385487127164187222250263
a4552590108332
randomised,46065901083215594134173232248275311352365
double-blind,499359010833978117157174210234275292307346386400
placebo54155901083395689304760010833166106145
and321460010833270110
active-controlled,33466001083326589105139174198232269309331353391408423459499513
parallel-group,38806001083397395128144160196212235276298336375415427
phase432960010833978111138174
24525600108334
trial4581600108321436092108
conducted471160010833169108148186219244278319
in505160010831554
the51276001083216096
USA.524560010834376117133
Lancet.54006001083316510430476101083316689103
2023;402:529-544.316661010833569103138150186223256269305339374398433469506520
41.30476200085366981
Jastreboff31476202083245683106127161201240259278
AM,344562020834096109
Kaplan357462020833568107123155193
LM,378762020833187100
Frías39066202083335268100126
JP,40526202083246064
et413562020833457
al.;4211620208331476072
Retatrutide43036202083357092125147168207229244283318
Phase464062020833573105132167
24826620208334
Obesity487962020834787123149164187220
Trial5119620208332496597112
Investigators.5250620208315538511914616918422325530476302083225980107121
Triple-Hormone-Receptor31866302083335065104120155178224263284343381419454477515550582616655677714736
Agonist394063020834179117156171197220
Retatrutide41786302083357093125147169207229245284318
for45146302083195678
Obesity461063020834787122149164186220
–4848630208335
A4901630208341
Phase496063020833573105131166
25144630208335
Trial.5197630208332496597112125
N5340630208345
Engl540363020833370109125
J3047640208324
Med.308664020835590130143
2023;389:514-526.324464020833468101136147182217251264299330361384418452485498
42.30476500085367086
Enebo315365020833370105145183
LB,33566502083316780
Berthelsen34556502083367192117155190206232267305
KK,37796502083357286
Kankam388565020833568106136170228
M,413265020835568
et422065020833456
al.42956502083324860
tolerability,43756502083225874109130163203218233248271305314
pharmacokinetics,470965020833877109130189221253290321337375410433448480507520
and524965020833270109
pharmacodynamics537765020833977110131304766020835790122159198230269301359374406434
of349866020833756
concomitant357166020833168106139176234249271304342364
administration395166020833271129144182197223246268301323338376414
of438266020833757
multiple445566020835895111133148187203238
doses471066020833876103138164
of489166020833757
cagrilintide496466020833264103125140155170208230245284319
with53006602083506688126
semaglutide544366020832661304767020835790129144182204219258293
2·433536702083344580
mg344767020835796
for35566702083185678
weight364767020835085100139177198
management:385967020835789127160199233291326365386400
a4272670208331
randomised,43176702083205391130168227242268303343355
controlled,468567020833268107128150187203218253293305
phase500367020833978110136171
1b518867020833469
trial.5270670208322435991106119
Lancet.54026702083326510330476802083316587101
2021;397:1736-1748.316368020833468101132141176209242252282311345380403434463494530543
43.30476901085367186
Frias31506902083325268100126
JP,32936902083246065
Deenadayalan337469020834681116155187226258289322337370408
S,379869020833346
Erichsen38606902083335470101139166201239
L,411669020833145
et417869020833356
al.42516902083314760
Efficacy4327690208333516986119151184217
and456169020833270109
safety46876902083265978112135168
of487269020833757
co-administered49456902083326992124163221236274289315338372393427467
once-weekly54296902083377630477001083316689141176212243259292
cagrilintide335970010833265104126142157172211233248287323
2·437027001083354581
mg380470010835897
with39227001083516790128
once-weekly407170010833876109143166219254289320337369
semaglutide446170010832661120153192208246268284323359
2·448407001083354581
mg494270010835897
in506070010831553
type51347001083225696132
25287700108334
diabetes:534270010833854861261623047710108322568497
a3165710108332
multicentre,321871010835997113136152184219258280302337349
randomised,35887101083215594133172232247274310350363
double-blind,397371010833877116156173208232273289305343383396
active-controlled,43907101083336690106139174198233270310332354392408424459500513
phase492471010833979112139175
25120710108334
trial.5175710108322446093109122
Lancet.531971010833166104137172195208
2023;402:720-730.304772010833468101136147182218251263297331365389420454489502
44.30477300085367490
Wharton315473020835796129150174211250
S,342173020833346
Blevins34847302083355186118134172198
T,370073020833241
Connery375973020834077115153188209243
L,402073020833145
et408373020833356
al.;4156730208332486073
GZGI424773020834382124139
Investigators.44047302083145284118145168183222254276313335362376
Daily47977302083457893108140
Oral495473020834769102118
GLP-1508973020834476112133164
Receptor527073020833570103137176198235257
Agonist304774020834179117156171197220
Orforglipron32837402083476890127149187202217256278315354
for36527402083185678
Adults374574020834179117132155182
with39437402083506688126
Obesity.408574020834786122149164186220230
N4330740208345
Engl439074020833371110125
J4530740208324
Med.457074020835489129142
2023;389:877-888.472774020833468101136148183217251264299332367385421457492505